New York State Common Retirement Fund Purchases 11,075 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

New York State Common Retirement Fund increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 15.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 81,565 shares of the company's stock after buying an additional 11,075 shares during the quarter. New York State Common Retirement Fund owned 0.17% of Amphastar Pharmaceuticals worth $2,365,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in Amphastar Pharmaceuticals by 4,151.3% during the 1st quarter. GAMMA Investing LLC now owns 38,644 shares of the company's stock valued at $1,120,000 after purchasing an additional 37,735 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Amphastar Pharmaceuticals by 14.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock worth $400,000 after purchasing an additional 1,694 shares during the period. Deutsche Bank AG increased its holdings in Amphastar Pharmaceuticals by 46.6% in the 4th quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock worth $1,265,000 after acquiring an additional 10,839 shares in the last quarter. ProShare Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 27.2% in the 4th quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock worth $514,000 after acquiring an additional 2,958 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Amphastar Pharmaceuticals by 9.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company's stock valued at $434,000 after buying an additional 1,262 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on AMPH shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $32.33.

Amphastar Pharmaceuticals Trading Down 0.6%

Shares of AMPH traded down $0.14 during trading hours on Friday, reaching $22.37. 329,130 shares of the company traded hands, compared to its average volume of 494,964. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 8.11 and a beta of 0.72. Amphastar Pharmaceuticals, Inc. has a 12-month low of $20.43 and a 12-month high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The stock's fifty day moving average price is $24.01 and its 200 day moving average price is $27.30.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.